Thus, EVE + EXE represents an important improvement in the management of postmenopausal women with HR+ HER2− advanced breast cancer progressing after nonsteroidal aromatase inhibitor treatment, regardless of ethnicity. Here, CYP19A1 is linked to breast carcinoma.